Janusz Rolski
About
Janusz Rolski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Janusz Rolski has authored 45 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in Janusz Rolski's work include Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (9 papers). Janusz Rolski is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (9 papers). Janusz Rolski collaborates with scholars based in Poland, United States and United Kingdom. Janusz Rolski's co-authors include Lorinda Simms, U. Gatzemeier, Tuncay Göksel, Giorgio V. Scagliotti, Keunchil Park, Mauro Zukin, Christian Manegold, Anders Mellemgaard, Piotr Serwatowski and Purvish Parikh and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.
In The Last Decade
Janusz Rolski
42 papers receiving 4.1k citations
Hit Papers
Peers
Janusz Rolski
Yaroslav Shparyk United States
Zsuzsanna Pápai Hungary
Niven Mehra Netherlands
Mauro Papotti Italy
J. Thaddeus Beck United States
Michael Millward Australia
Paul Frankel United States
P. Murawa Poland
Tiffany A. Traina United States
Vincenza Conteduca Italy
Citations per year, relative to Janusz Rolski Janusz Rolski (= 1×)
peers
Yaroslav Shparyk
Countries citing papers authored by Janusz Rolski
Since
Specialization
Citations
This map shows the geographic impact of Janusz Rolski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janusz Rolski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janusz Rolski more than expected).
Fields of papers citing papers by Janusz Rolski
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Janusz Rolski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janusz Rolski. The network helps show where Janusz Rolski may publish in the future.
Co-authorship network of co-authors of Janusz Rolski
This figure shows the co-authorship network connecting the top 25 collaborators of Janusz Rolski. A scholar is included among the top collaborators of Janusz Rolski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janusz Rolski. Janusz Rolski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cybulska-Stopa, Bożena, Renata Pacholczak‐Madej, Grażyna Kamińska‐Winciorek, et al.. (2020). First-Line Treatment of Advanced/Metastatic Melanoma with Anti-PD-1 Antibodies: Multicenter Experience in Poland. Immunotherapy. 13(4). 297–307.
2.
Cybulska-Stopa, Bożena, et al.. (2020). Real-world treatment practice in patients with advanced melanoma. Współczesna Onkologia. 24(2). 118–124.
3.
Robertson, J.F.R., Justin P.O. Lindemann, Antonio Llombart‐Cussac, et al.. (2012). Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Research and Treatment. 136(2). 503–511.
4.
Rolski, Janusz, et al.. (2012). The possibility of lapatinib treatment for breast cancer patients with central nervous system metastases. Case study and literature review. Współczesna Onkologia. 6(6). 582–585.
5.
Pritchard, Kathleen I., Janusz Rolski, Zsuzsanna Pápai, et al.. (2010). Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Research and Treatment. 123(2). 453–461.
6.
Martín, Miguel, John R. Mackey, Tadeusz Pieńkowski, et al.. (2010). Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer. Cancer Research. 70(24_Supplement). S4–3.
7.
Valero, Vicente, John Forbes, Mark D. Pegram, et al.. (2010). Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. Journal of Clinical Oncology. 29(2). 149–156.
8.
Roila, Fausto, Janusz Rolski, Rodryg Ramlau, et al.. (2009). Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Annals of Oncology. 20(11). 1867–1873.
9.
Tan, E.H., Janusz Rolski, Tomasz Grodzki, et al.. (2009). Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 20(7). 1249–1256.
10.
Scagliotti, Giorgio V., Keunchil Park, Shekar Patil, et al.. (2009). Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study. European Journal of Cancer. 45(13). 2298–2303.
11.
Grunberg, Steven M., Janusz Rolski, Zeba Aziz, et al.. (2009). Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 10(6). 549–558.
12.
Scagliotti, Giorgio V., Purvish Parikh, Joachim von Pawel, et al.. (2008). Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(21). 3543–3551.
13.
Ziobro, Marek, et al.. (2008). Effects of palliative treatment with temozolomide in patients with high-grade gliomas.. PubMed. 42(3). 210–5.
14.
Ramlau, Rodryg, Élisabeth Quoix, Janusz Rolski, et al.. (2008). A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(7). 735–744.
15.
Rolski, Janusz, et al.. (2007). Targeted therapy Part I. Signalling by tyrosine kinase receptors. Contemporary Oncology/Współczesna Onkologia. 11(7). 331–336.
16.
Tan, Eng-Huat, Tomasz Grodzki, Claus-Peter Schneider, et al.. (2007). PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S451–S451.
17.
Rolski, Janusz, et al.. (2007). 6501 ORAL Global Lung Oncology Branch trial 3 (GLOB 3): Quality of Life (QoL) results of a randomised multinational Phase III trial of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements. 5(4). 356–356.
18.
Rolski, Janusz & Marek Pawlicki. (2003). Treatment of cancer associated anaemia. Contemporary Oncology/Współczesna Onkologia. 5(5). 222–225.
19.
Rolski, Janusz, et al.. (2003). Management of disease related anaemia in cancer patients. Contemporary Oncology/Współczesna Onkologia. 6(10). 654–663.
20.
Jassem, Jacek, et al.. (1992). Randomized Phase II Trial of High-Dose 4’-Epi-Doxorubicin + Cyclophosphamide versus High-Dose 4’-Epi-Doxorubicin + Cisplatin in Previously Untreated Patients with Extensive Small Cell Lung Cancer. Oncology. 49(5). 327–332.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Yaroslav Shparyk Breakdown of academic impact, for papers by Zsuzsanna Pápai Breakdown of academic impact, for papers by Niven Mehra Breakdown of academic impact, for papers by Mauro Papotti Breakdown of academic impact, for papers by J. Thaddeus Beck Breakdown of academic impact, for papers by Michael Millward Breakdown of academic impact, for papers by Paul Frankel Breakdown of academic impact, for papers by P. Murawa Breakdown of academic impact, for papers by Tiffany A. Traina Breakdown of academic impact, for papers by Vincenza Conteduca